Budget Impact Analysis of Idecabtagene Vicleucel for the Treatment of Adult Patients with Relapsed or Refractory Multiple Myeloma in the US - Clinical Drug Investigation
Source : https://link.springer.com/article/10.1007/s40261-022-01215-w
Background Gene therapy is known to be unaffordable to those who need it the most; however, evidence on the financial impact is limited. Objective This study aimed to estimate the budget impact and affordability of the gene therapy idecabtagene vicleucel for the treatment of adult patients with relapsed or refractory multiple myeloma (rrMM) in the US over a 3-year period from the payer healthcare perspective.
Conclusions: This study suggests that the high cost of the gene therapy idecabtagene vicleucel is justifiable due to the low number of rrMM patients.